Nature Reviews Clinical Oncology - Table of Contents alert Volume 11 Issue 7

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
July 2014 Volume 11 Number 7
Impact Factor 15.031 *	In this issue Research Highlights News and Views Reviews Perspectives Correspondence Also this month  Featured article: Metronomics: towards personalized chemotherapy? Nicolas André, Manon Carré & Eddy Pasquier
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Outlook Cancer Cancer kills millions of people across the globe every year. But the development of targeted medicines, novel drug delivery technologies and clinical research data offer a glimpse towards a cancer-free future.  Access the Outlook free online for six months.  Produced with support from Celgene Corporation.
RESEARCH HIGHLIGHTS Top Chemotherapy: NEPA—a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting Published online: 03 June 2014 p377 | doi:10.1038/nrclinonc.2014.92 PDF Breast cancer: RARRES3—suppressing metastases to the lung in breast cancer Published online: 10 June 2014 p378 | doi:10.1038/nrclinonc.2014.103 PDF Paediatric oncology: Triple therapy avoids need for radiation in children with ALL Published online: 27 May 2014 p378 | doi:10.1038/nrclinonc.2014.93 PDF Bladder cancer: Accelerating MVAC Published online: 27 May 2014 p378 | doi:10.1038/nrclinonc.2014.94 PDF Breast cancer: TNBC: can we treat the untargetable? Published online: 20 May 2014 p379 | doi:10.1038/nrclinonc.2014.88 PDF Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer Published online: 10 June 2014 p379 | doi:10.1038/nrclinonc.2014.99 PDF Targeted therapies: Ibrutinib resonates with us Published online: 17 June 2014 p380 | doi:10.1038/nrclinonc.2014.105 PDF IN BRIEF From ASCO—prostate cancer: Chemohormonal therapy leads the way in prostate cancer | From ASCO—colorectal cancer: Cetuximab or bevacizumab with chemo: take your pick | From ASCO—breast cancer: Ovarian function suppression plus exemestane improves DFS PDF Clinical Oncology JOBS of the week Postdoc Research Scholar - Molecular Oncology Washington University School of Medicine Thoracic / Head & Neck Medical Oncology MD Anderson Cancer Center Postdoctoral Fellowship -Molecular Biology, USA Wayne State University Research fellow (resident physician) Charite - Universitaetsmedizin Berlin Assistant or Associate Professor Boston Children's Hospital and Dana-Farber Cancer Institute More Science jobs from Clinical Oncology EVENT ESMO 2014 Congress 26.09.14 Madrid, Spain More science events from
NEWS AND VIEWS		Top
Lung cancer: Dropping bars or rising hoops—phase III outcomes of NSCLC Herbert H. Loong & Tony S. K. Mok Published online: 20 May 2014 p381 | doi:10.1038/nrclinonc.2014.91 Over the past three decades, the interpretation of clinical trial outcomes in studies of advanced-stage non-small-cell lung cancer has changed. The robustness of findings from these trials has been called into question. We believe this change is a reflection of the improved understanding of molecular-based therapeutics and continued advances in this field. Full Text | PDF
Breast cancer: Post-mastectomy radiotherapy reduces recurrence and mortality Roberto Orecchia Published online: 03 June 2014 p382 | doi:10.1038/nrclinonc.2014.95 The recent results of the Early Breast Cancer Trialists' Cooperative Group meta-analysis have demonstrated that post-mastectomy radiotherapy reduces breast cancer recurrence and mortality in women with positive axillary lymph nodes—independently from the number of the lymph nodes involved—with no significant effect in patients with node-negative axillary status. Full Text | PDF
REVIEWS		Top
The clinical development of MEK inhibitors Yujie Zhao & Alex A. Adjei Published online: 20 May 2014 p385 | doi:10.1038/nrclinonc.2014.83 MEK1 and MEK2 have key roles in tumorigenesis and, therefore, represent promising targets for cancer therapy; however, MEK1/2 inhibitors have been shown to have efficacy in only a narrow range of cancer types, mainly tumours that harbour BRAF or NRAS mutations. In this article, the clinical experience with MEK inhibitors to date is reviewed, and potential approaches to overcoming therapeutic resistance and increasing the efficacy of treatment are discussed. Abstract | Full Text | PDF
Circulating tumour cells—monitoring treatment response in prostate cancer David T. Miyamoto, Lecia V. Sequist & Richard J. Lee Published online: 13 May 2014 p401 | doi:10.1038/nrclinonc.2014.82 Circulating tumour cells (CTCs) might be representative of the tumour burden and might also provide information on tumour cell biology. As such, these cells hold promise in the prediction and monitoring of response to anticancer therapy. In this Review, the authors highlight the challenges of monitoring treatment response in metastatic castrate-resistance prostate cancer and discuss the developments in CTC analyses that have increased the value of these cells as potential biomarkers in this disease. Abstract | Full Text | PDF
Metronomics: towards personalized chemotherapy? Nicolas André, Manon Carré & Eddy Pasquier Published online: 10 June 2014 p413 | doi:10.1038/nrclinonc.2014.89 Metronomic chemotherapy has undergone major advances as an antiangiogenic therapy. The discovery of the pro-immune properties of chemotherapy has established the intrinsic multitargeted nature of this therapeutic approach. Andre et al. describe the complex mechanisms of action of metronomic chemotherapy, and discuss the latest clinical data in both adult and paediatric populations, highlighting its potential role in the era of personalized medicine. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Implementing personalized cancer care Richard L. Schilsky Published online: 01 April 2014 p432 | doi:10.1038/nrclinonc.2014.54 A key challenge in oncology is obtaining drugs predicted to be beneficial based on the patient's tumour profile. One solution is creation of a national facilitated access programme and registry for off-label use of targeted anti-cancer drugs. Schilsky discusses several key elements of implementing personalized cancer care services in an oncology practice setting and offers solutions to some of the obstacles of making personalized medicine available to many patients. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Gastric cancer drug trials—are women second class citizens? Lishi Wang, Yan Jiao, Yun Jiao, Yanhong Cao & Weikuan Gu Published online: 03 June 2014 p438 | doi:10.1038/nrclinonc.2013.231-c1 Full Text | PDF
Reply: Gastric cancer drug trials—are women second class citizens? Manish A. Shah Published online: 03 June 2014 p438 | doi:10.1038/nrclinonc.2013.231-c2 Full Text | PDF
Advertisement
Nature Reviews Call for Cover Images! Wanted - an eye-catching image per journal to feature on all 12 covers of the 2015 issues of the clinical Nature Reviews titles. We are offering the opportunity for one person's image to appear on each cover for a whole year! PLUS we'll send you a print of the cover as a thank you.  Visit for more information
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.